FDA Weighs Approval of a Lucrative Alzheimer鈥檚 Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen鈥檚 drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.